Device Trial Radar · NCT04267562
Minitouch Endometrial Ablation System Treatment for Menorrhagia: An Evaluation of Safety & Effectiveness
Last checked: Nov 20, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
219
Actual
Start
Feb 28, 2020
Primary completion
Jul 20, 2022
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- MicroCube, LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 13, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 30 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The EASE Clinical Trial is prospective, multi-center, single-arm (open-label), non-randomized, clinical trial to evaluate the Minitouch Endometrial Ablation System ("Minitouch System") in premenopausal women with menorrhagia.
Conditions
- Menorrhagia
- Heavy Menstrual Bleeding
- Heavy Uterine Bleeding
Interventions
Minitouch SystemDevice
The investigational treatment (endometrial ablation) will be performed utilizing the Minitouch System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Trial Participants With Reduction in Menstrual Bleeding (PBLAC Score of ≤75)Time frame: Month 12 post-procedure
- Number of Trial Participants With Device or Procedure-related Serious Adverse EventsTime frame: Month 12 post-procedure
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
CMB Research
Newburgh, Indiana
Amy Brenner, MD & Associates
Mason, Ohio
Women's Health Texas (Women Partners in Health)
Austin, Texas
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.